Holen Sie sich die Stockscreener-App
71.93
0.75%
-0.54
Vorhandelsmarkt:
73.00
1.07
+1.49%
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte Gains 15.3% In A Year: Is There Room For Further Growth? - Barchart
Short Interest in Incyte Co. (NASDAQ:INCY) Decreases By 13.1% - MarketBeat
INCY (Incyte) GF Value Rank : 8 (As of Jan. 20, 2025) - GuruFocus.com
Hennion & Walsh Asset Management Inc. Purchases 11,120 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
What You Need To Know Ahead Of Incyte's Earnings Release - Barchart
Fed. Circ. Urged To Keep Block Of Sun Pharma Alopecia Drug - Law360
Contravisory Investment Management Inc. Has $750,000 Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
CHURCHILL MANAGEMENT Corp Has $12.36 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Claro Advisors LLC Takes Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
JP Morgan 2025: Incyte expects period of ‘defining catalysts’ - Yahoo Finance
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Warm Autoimmune hemolytic anemia (WAIHA) Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Rigel Pharma, Incyte Crp., Sanofi, Johnson & Johnson, Janssen R&D - Barchart
Incyte's SWOT analysis: navigating patent cliff with promising pipeline - Investing.com
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
DPP-led Effort For Incyte Leads To Deal Of The Year Honors - Town Square Delaware LIVE
Incyte's (INCY) "Market Perform" Rating Reiterated at JMP Securities - MarketBeat
Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline - Benzinga
Warm Autoimmune hemolytic anemia (WAIHA) Market Poised - openPR
Pallas Capital Advisors LLC Makes New $1.01 Million Investment in Incyte Co. (NASDAQ:INCY) - MarketBeat
Has Incyte (INCY) Outpaced Other Medical Stocks This Year? - MSN
Anal Cancer Market on Track for Major Expansion by 2034, - openPR
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Analysts Set Incyte Co. (NASDAQ:INCY) Target Price at $76.29 - MarketBeat
Incyte: Multiple Drug Launches Bode Well For Future Growth - Seeking Alpha
Incyte (NASDAQ:INCY) Given "Neutral" Rating at Cantor Fitzgerald - MarketBeat
Incyte Corporation (INCY) Announces Executive Leadership Change - GuruFocus.com
Incyte Announces Retirement of Executive VP Barry Flannelly - TipRanks
JPMorgan Chase & Co. Reduces Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2025 - BioSpace
Incyte (MEX:INCY) Earnings Yield % : 0.09% (As of Jan. 08, 2025) - GuruFocus.com
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
Follicular Lymphoma Market Expected to rise, 2034 | - openPR
CWA Asset Management Group LLC Acquires Shares of 27,984 Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock rises Friday, still underperforms market - MarketWatch
Centre Asset Management LLC Has $9.40 Million Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
CDK2/cyclin E1 inhibitors disclosed in Incyte patent - BioWorld Online
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Principal Financial Group Inc. Has $14.59 Million Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock rises Tuesday, still underperforms market - MarketWatch
Is Incyte Stock Outperforming The Dow? - Barchart
Is Incyte Stock Outperforming the Dow? - Inkl
Franklin Resources Inc. Sells 50,188 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Sanctuary Advisors LLC Has $1.51 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte price target raised to $70 from $68 at Wells Fargo - Yahoo Finance
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
The Analyst Verdict: Incyte In The Eyes Of 15 Experts - Benzinga
Wells Fargo & Company Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Analysts Set Incyte Co. (NASDAQ:INCY) Target Price at $76.18 - MarketBeat
Incyte corp principal accounting officer Tray Thomas sells $90,967 in stock - Investing.com India
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Insider Selling: Incyte Co. (NASDAQ:INCY) Insider Sells 650 Shares of Stock - MarketBeat
Incyte corp principal accounting officer Tray Thomas sells $90,967 in stock By Investing.com - Investing.com South Africa
Incyte (NASDAQ:INCY) Earns Neutral Rating from Analysts at UBS Group - MarketBeat
Orion Portfolio Solutions LLC Purchases New Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Wellington Management Group LLP Has $4.74 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte to Present at Upcoming Investor Conference - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Toronto Dominion Bank Purchases 7,812 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
4.62%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):